Filing Flows › Dare Bioscience (DARE) › Q1 2025
Dare Bioscience (DARE) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 13, 2025
Dare Bioscience (DARE) reported revenue of $25K for the first quarter 2025 (Q1 2025), +173% from a year earlier.
Dare Bioscience, Q1 2025: revenue $25K (+173% year over year), net loss $4.4M, operating cash flow −$5.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $25K | — | +173% |
| Operating profit | −$4.6M | — | — |
| Net earnings | −$4.4M | — | — |
| Operating cash flow | −$5.5M | — | — |
What changed
Revenue was $25K in Q1 2025, up 173% year over year.
Operating costs exceeded revenue by $4.6M, an operating margin of -18016.7%. Total costs fell 24% while revenue rose 173%. The quarter ended with a net loss of $4.4M.
Operating cash flow was −$5.5M. Non-cash charges added back $158K of depreciation and amortization and $377K of share-based compensation. Working capital and other items used $1.6M. Capital expenditures of $157K exceeded it, leaving free cash flow of −$5.6M.
Questions
What was Dare Bioscience's revenue in the first quarter 2025?
Dare Bioscience (DARE) reported revenue of $25K for the first quarter 2025 (Q1 2025), +173% from a year earlier.
Source: Dare Bioscience 10-Q on SEC EDGAR.